China National Medical Products Administration Approval Summary: Anlotinib for the Treatment of Advanced Non-Small Cell Lung Cancer After Two Lines of Chemotherapy

Cancer Communications - United Kingdom
doi 10.1186/s40880-019-0383-7
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Approval Summary: Pemetrexed Maintenance Therapy of Advanced/Metastatic Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)

Oncologist
Cancer ResearchMedicineOncology
2010English

Palliative Chemotherapy for Advanced Non-Small Cell Lung Cancer

BMJ
1994English

A Case of Multiple Transient Ischemic Attacks After Chemotherapy for Advanced Non-Small Cell Lung Cancer

Japanese Journal of Lung Cancer
OncologyRespiratory MedicinePulmonary
2006English

Targeted Therapy for the Treatment of Advanced Non-Small Cell Lung Cancer

Chest
CardiologyCritical CareCardiovascular MedicineIntensive Care MedicinePulmonaryRespiratory Medicine
2005English

Oncologic Treatment of Non-Small Cell Lung Cancer Part B: Adjuvant Chemotherapy for Resected Non-Small Cell Lung Carcinoma

2013English

Afatinib Treatment in Advanced Non-Small Cell Lung Cancer

Lung Cancer: Targets and Therapy
Oncology
2011English

Bevacizumab Combination Chemotherapy in Clinical Practice for Advanced Non-Squamous Non-Small Cell Lung Cancer

Japanese Journal of Lung Cancer
OncologyRespiratory MedicinePulmonary
2013English

Treatment Results Including More Than Third-Line Chemotherapy for Patients With Advanced Non-Small Cell Lung Cancer

Oncology Letters
Cancer ResearchOncology
2010English

P1.03-16 Anlotinib Inhibits Angiogenesis of Refractory Advanced Non-Small Cell Lung Cancer via Blocking CCL2 Expression

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy